On June 22, Kardigan fell 9% in pre-market trading, trading at $20.01/share, with turnover of approximately $415,700.

On the news front, the stock is experiencing a technical pullback after its IPO debut on June 19, during which shares surged over 42% from the $16 offering price. The IPO raised approximately $400 million through the issuance of 25 million shares at the top end of its $14-$16 pricing range, with underwriters granted a 30-day option to purchase up to 3.75 million additional shares. The offering settlement is expected to close on June 22.

Kardigan is a clinical-stage precision cardiovascular therapeutics company with three late-stage pipeline assets — Danicamtiv, Ataciguat, and Tonlamarsen — targeting indications with no currently approved therapies. The company has not yet generated commercial revenue and reported net losses of $88.66 million and $192 million in its two most recent fiscal years, with $287 million in cash and equivalents as of March 31.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)